Furthermore, Dr Reddy's has also hinted that it is vertically integrated and fully prepared to capture the GLP-1 ...

Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 full-year ...

While Ozempic has been shown to lead to weight loss as a side effect, it's not without risks. According to the Cleveland ...

On November 5, the US Food and Drug Administration (FDA) updated the labels for all glucagon-like peptide 1 receptor agonists (GLP-1 RA) with a warning about pulmonary aspiration during general ...

Qiagen NV added to its growing roster of panels cleared by the U.S. FDA in 2024 with the agency’s nod for its Qiastat-Dx Meningitis/Encephalitis assay. The clearance validates Qiagen’s strategy of ...

GLP-1s, or glucagon-like peptide-1 agonist drugs, are seemingly everywhere. In recent years, this class of weight-loss and Type 2 diabetes medication has become not only a household name but ...

Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) set up its second overseas regulatory office in Washington, four ...

The Denmark-based drug maker Zealand Pharma said Tuesday that its experimental weight-loss drug could help patients lose ...

Low-income patients' access to blockbuster weight-loss drugs through Medicaid remains limited, a new KFF analysis has found.

Medications like Ozempic and Wegovy, which are used to treat type 2 diabetes and boost weight loss, may also help reduce knee ...

Drugs for diabetic kidney disease treatment have greatly expanded, allowing research and consensus on their optimal use.

Greatest increase in SGLT2 inhibitor use seen in subgroups with cardiovascular disease; greatest increase in GLP-1 RA for those with obesity ...